IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentees

Sanberg et al.

Docket No. USF-005

Seetal No.:

10/621,061

Group Art Univ. 1636

Confirmation No. 8835

Examiner Nancy Vogal

Timber

HUMAN IMMUNOSUPPRESSIVE PROTEIN

Affidavir under Rule 132

A PRINCE SAMPLE

- I, William R. Gower, Jr., am an inventor of the above-captioned patent application. I am Professor of Biochemistry, Molecular Biology, Physiology, and Biophysics at the University of South Florida, the owner of the above-captioned patent application. I have a financial interest in the patent application.
- I received my B.A. from the University of Delawars; and my Ph.D. from Ohio State University.
- 3. I am the first author on the article excided "hNT neurous express an immunosuppressive protein that blocks T-lymphocyte proliferation and intedenkin-2 production," published in Journal of Neuroimmunology 125:163-113, 2022.
- 4. I have reviewed the May 3, 2007, Office Action and the patent application. I am providing this Affidavit and accompanying papers because the Office Action dated May 3, 2007, smed that there was no evidence to show the reduction to practice before the publication date of the above-mentioned article.
- 5. My co-authors and I reviewed our files for evidence of having reduced the invention to practice by producing an early draft of the manuscript which was subsequently published. Accompanying this affidavic is a copy of the marked-up initial draft from the journal, indicating the manuscript was 1" submitted 9/11/01. The marked-up draft was returned on January 7, 2002, with a letter requesting minimal charges.
- 6. The draft manuscript of 9/11/01 is substantially the same as the printed article. All the test data and conclusions in the draft manuscript are the same as the printed article.

I bereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully yours,

Marita Mari

William R. Gower, PhD